Management of Subconjunctival Hemorrhage 2 Weeks After Cataract Surgery
A subconjunctival hemorrhage occurring 2 weeks after cataract surgery requires no specific treatment and should be managed with observation and reassurance, as it is self-limiting and resolves within 1-2 weeks without affecting visual acuity. 1
Clinical Approach
Immediate Assessment
First, confirm this is truly a benign subconjunctival hemorrhage by verifying:
- Visual acuity is preserved - any vision loss suggests a more serious complication requiring urgent evaluation 1
- No pain beyond mild irritation - significant pain could indicate infection, inflammation, or other complications
- No signs of infection - check for purulent discharge, severe injection, or anterior chamber reaction
- The hemorrhage is confined to the subconjunctival space - not intraocular bleeding
Medication Review
If the patient is on antiplatelet therapy (aspirin or clopidogrel), continue the medication and monitor for bleeding 1. The guidelines are explicit that subconjunctival bleeding in patients on antiplatelet therapy should not prompt discontinuation of these medications, as:
- The bleeding is self-limiting
- Does not affect visual acuity
- Resolves within 1-2 weeks
- The cardiovascular risks of stopping antiplatelet therapy outweigh the minimal ocular risk
However, if the patient has recurrent or unusually extensive subconjunctival hemorrhage, obtain:
- Complete blood count (to rule out thrombocytopenia)
- INR and aPTT (to investigate for coagulopathy) 1
Only discontinue antiplatelet therapy if laboratory testing reveals thrombocytopenia or a coagulopathy requiring further investigation 1.
Patient Counseling
Provide clear reassurance:
- This is a common, benign finding that can occur after cataract surgery, particularly with certain anesthetic techniques 2, 3
- The redness will resolve spontaneously over 1-2 weeks 1
- Vision will not be affected 1
- No specific treatment is needed
When to Escalate Care
Refer urgently or re-evaluate immediately if:
- Visual acuity decreases (suggests intraocular hemorrhage, retinal complications, or endophthalmitis) 4
- Severe pain develops (consider endophthalmitis, which occurs in 1 in 30,000-185,000 cases) 5
- Signs of infection appear
- The hemorrhage is accompanied by proptosis or restricted eye movements (suggests retrobulbar hemorrhage)
Important Context
Subconjunctival hemorrhage is notably more common with:
- Superficial peribulbar anesthesia (18% incidence vs 0.5% with conventional peribulbar block) 2
- Subconjunctival anesthetic injections (significantly higher rates with lidocaine injection) 3
- Patients on anticoagulation or antiplatelet therapy 1, 6, 7
The 2022 CHEST guidelines specifically address minor ophthalmologic procedures and recommend continuing vitamin K antagonists (warfarin) for cataract surgery, noting that bleeding complications are typically self-limiting (subconjunctival bleeds, dot hyphemas) with no compromise to visual acuity 8.
Common Pitfall to Avoid
Do not stop antiplatelet or anticoagulant therapy reflexively. The cardiovascular and thromboembolic risks of interrupting these medications far exceed the minimal risk posed by a benign subconjunctival hemorrhage. Only consider medication adjustment after appropriate laboratory evaluation reveals a specific hemostatic abnormality requiring intervention 1, 8.